125 related articles for article (PubMed ID: 38447327)
1. Sodium citrate buffer improves pazopanib solubility and absorption in gastric acid-suppressed rat model.
Muhammad HJ; Shimada T; Fujita A; Sai Y
Drug Metab Pharmacokinet; 2024 Apr; 55():100995. PubMed ID: 38447327
[TBL] [Abstract][Full Text] [Related]
2. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.
Tan AR; Gibbon DG; Stein MN; Lindquist D; Edenfield JW; Martin JC; Gregory C; Suttle AB; Tada H; Botbyl J; Stephenson JJ
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1635-43. PubMed ID: 23636448
[TBL] [Abstract][Full Text] [Related]
3. Administration of erlotinib in apple juice overcomes decreased absorption in a rat model of gastric acid suppression.
Shimada T; Okano M; Yamada M; Ogawa Y; Ueda A; Nagase K; Sai Y
Drug Metab Pharmacokinet; 2020 Dec; 35(6):534-538. PubMed ID: 33028492
[TBL] [Abstract][Full Text] [Related]
4. Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility.
Ware JA; Dalziel G; Jin JY; Pellett JD; Smelick GS; West DA; Salphati L; Ding X; Sutton R; Fridyland J; Dresser MJ; Morrisson G; Holden SN
Mol Pharm; 2013 Nov; 10(11):4074-81. PubMed ID: 24099279
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and absorption of the anticancer agents dasatinib and GDC-0941 under various gastric conditions in dogs--reversing the effect of elevated gastric pH with betaine HCl.
Pang J; Dalziel G; Dean B; Ware JA; Salphati L
Mol Pharm; 2013 Nov; 10(11):4024-31. PubMed ID: 23980865
[TBL] [Abstract][Full Text] [Related]
6. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib.
Yin OQ; Gallagher N; Fischer D; Demirhan E; Zhou W; Golor G; Schran H
J Clin Pharmacol; 2010 Aug; 50(8):960-7. PubMed ID: 20498287
[TBL] [Abstract][Full Text] [Related]
7. Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations.
Walravens J; Brouwers J; Spriet I; Tack J; Annaert P; Augustijns P
Clin Pharmacokinet; 2011 Nov; 50(11):725-34. PubMed ID: 21973269
[TBL] [Abstract][Full Text] [Related]
8. Esomeprazole immediate release tablets: Gastric mucosa ex vivo permeation, absorption and antisecretory activity in conscious rats.
Benetti C; Flammini L; Vivo V; Colombo P; Colombo G; Elviri L; Scarpignato C; Buttini F; Bettini R; Barocelli E; Rossi A
J Control Release; 2016 Oct; 239():203-10. PubMed ID: 27574989
[TBL] [Abstract][Full Text] [Related]
9. Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole.
Pohl O; Osterloh I; Lecomte V; Gotteland JP
Int J Clin Pharmacol Ther; 2013 Jan; 51(1):26-33. PubMed ID: 23110788
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects.
Nguyen L; Holland J; Mamelok R; Laberge MK; Grenier J; Swearingen D; Armas D; Lacy S
J Clin Pharmacol; 2015 Nov; 55(11):1293-302. PubMed ID: 25907407
[TBL] [Abstract][Full Text] [Related]
11. Utilization of Lipophilic Salt and Phospholipid Complex in Lipid-Based Formulations to Modulate Drug Loading and Oral Bioavailability of Pazopanib.
Jadhav K; Sirvi A; Janjal A; Kashyap MC; Sangamwar AT
AAPS PharmSciTech; 2024 Mar; 25(3):59. PubMed ID: 38472682
[TBL] [Abstract][Full Text] [Related]
12. Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole.
Yang E; Kim S; Kim B; Kim B; Kim Y; Park SS; Song GS; Yu KS; Jang IJ; Lee S
Br J Clin Pharmacol; 2022 Jul; 88(7):3288-3296. PubMed ID: 35146797
[TBL] [Abstract][Full Text] [Related]
13. Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers.
Zhou J; Quinlan M; Glenn K; Boss H; Picard F; Castro H; Sellami D
Br J Clin Pharmacol; 2016 Oct; 82(4):1022-9. PubMed ID: 27277189
[TBL] [Abstract][Full Text] [Related]
14. When Bioequivalence in Healthy Volunteers May not Translate to Bioequivalence in Patients: Differential Effects of Increased Gastric pH on the Pharmacokinetics of Levothyroxine Capsules and Tablets.
Seng Yue C; Benvenga S; Scarsi C; Loprete L; Ducharme MP
J Pharm Pharm Sci; 2015; 18(5):844-55. PubMed ID: 26670370
[TBL] [Abstract][Full Text] [Related]
15. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype.
Kagami T; Sahara S; Ichikawa H; Uotani T; Yamade M; Sugimoto M; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2016 May; 43(10):1048-59. PubMed ID: 26991399
[TBL] [Abstract][Full Text] [Related]
16. The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure.
Krens SD; Lubberman FJE; van Egmond M; Jansman FGA; Burger DM; Hamberg P; Vervenne WL; Gelderblom H; van der Graaf WTA; Desar IME; van Herpen CML; van Erp NP
Int J Cancer; 2021 Jun; 148(11):2799-2806. PubMed ID: 33428771
[TBL] [Abstract][Full Text] [Related]
17. In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer.
Liu F; Shokrollahi H
Int J Pharm; 2015 May; 485(1-2):152-9. PubMed ID: 25746736
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic understanding of the effect of PPIs and acidic carbonated beverages on the oral absorption of itraconazole based on absorption modeling with appropriate in vitro data.
Fotaki N; Klein S
Mol Pharm; 2013 Nov; 10(11):4016-23. PubMed ID: 23947755
[TBL] [Abstract][Full Text] [Related]
19. Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.
McAlister RK; Aston J; Pollack M; Du L; Koyama T; Chism DD
Oncologist; 2018 Jun; 23(6):686-692. PubMed ID: 29487220
[TBL] [Abstract][Full Text] [Related]
20. Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials.
Mir O; Touati N; Lia M; Litière S; Le Cesne A; Sleijfer S; Blay JY; Leahy M; Young R; Mathijssen RHJ; Van Erp NP; Gelderblom H; Van der Graaf WT; Gronchi A
Clin Cancer Res; 2019 Mar; 25(5):1479-1485. PubMed ID: 30765389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
